Discover Products, Get Discovered.
Individuals find the right products. Businesses reach the right audience. One platform, free for both.
Individuals find the right products. Businesses reach the right audience. One platform, free for both.
Since 2023, Ohara Pharmaceutical has backed 2 African startups across 3 disclosed funding rounds totaling $39.6M, most heavily in Health Tech.
Ohara Pharmaceutical Co., Ltd. is a Japanese pharmaceutical manufacturer that develops and supplies orphan drugs and generic medicines. According to its official English website, the company focuses on responding to the needs of patients and medical professionals by providing high quality, affordable treatments and specialized therapies. Location details and broader corporate structure are not stated in relation to its role as an investor in Africa, so they are not included here. In Africa, Ohara Pharmaceutical has an active investment track record in health technology between June 2023 and April 2025, committing a total of 39.6 million dollars across three funding rounds. The company has participated in a Series B round, a venture round that is not specified by stage, and another round categorized as Other, all focused on health tech. Its capital has been directed to Kenya and Nigeria, backing MYDAWA in Kenya and Helium Health in Nigeria, which provide digital tools, medicines, and healthcare essentials. Across these African deals, Ohara Pharmaceutical has invested alongside a network of international co investors that includes AAIC Investment, Creadev, Investment Fund for Developing Countries, Alta Semper Capital, IFU, LCY Chemical, Anne Wojcicki, Western Technology Investment, Capria Ventures, Angaza Capital, AXA Investment Managers, Flat World Partners, Global Ventures, and Tencent. This pattern highlights Ohara Pharmaceutical’s role as a strategic health sector investor working with established regional and global partners in African health technology.
Data updated · Sep 8, 2026
Ohara Pharmaceutical has backed 2 African startups across 3 disclosed funding rounds tracked on Liners, totaling $39.6M since 2023.
Mostly Other: 1 of its 3 tracked rounds are at that stage, followed by Venture (Round not Specified) (1).
Its tracked rounds lean toward Health Tech (3).
Ohara Pharmaceutical most often shares rounds with AAIC Investment (2 shared deals), Creadev (2 shared deals), IFU (1 shared deal).
Ohara Pharmaceutical has invested a total of 39.6 million dollars in African health tech companies between June 2023 and April 2025. These investments span three funding rounds across Kenya and Nigeria, focused on MYDAWA and Helium Health.
Ohara Pharmaceutical’s African portfolio includes MYDAWA in Kenya and Helium Health in Nigeria. MYDAWA enables customers to order medicines and healthcare essentials with fast delivery, while Helium Health provides digital tools and financing for healthcare providers.
Ohara Pharmaceutical has co invested in Africa alongside partners such as AAIC Investment, Creadev, Investment Fund for Developing Countries, Alta Semper Capital, IFU, LCY Chemical, Anne Wojcicki, Western Technology Investment, Capria Ventures, Angaza Capital, AXA Investment Managers, Flat World Partners, Global Ventures, and Tencent. These collaborations have taken place in funding rounds for MYDAWA and Helium Health.
Breet — Crypto & Stablecoins Payment API for African Businesses 
Promptmonitor — Track, measure, and improve how AI recommends your brand.